Skip to main content
Download PDF

Volume 1 Supplement 1

Abstracts of the 28th Annual Scientific Meeting of the Society for Immunotherapy of Cancer (SITC)

Expression of cancer-testis antigen in patients with non-small cell lung cancer and its clinical relevance

Journal for ImmunoTherapy of Cancer volume 1, Article number: P246 (2013) Cite this article

Background

Lung cancer is the most common cause of cancer-related mortality worldwide. Survival rates after non-small cell lung cancer (NSCLC) diagnosis still remain poor, despite standardization of surgery and adjuvant treatment. Cancer testis (CT) antigens as targets for immunotherapy in cancer patients have been heavily investigated. We aim to evaluate the expression of CT antigens in non-small cell lung cancer and the correlation with the clinical characteristics.

Methods

The expression of MAGE-A3, MAGE-A4, MAGE-C2 and NY-ESO-1 in fresh cancer tissues from 113 patients with non-small cell lung cancer were analyzed by RT-PCR. The expression of HLA-A2 was detected by flow cytometry.

Results

49.6% non-small cell lung cancer samples were HLA-A2 positive. CT antigens were frequently expressed in non-small cell lung cancer. The expression percentage of each gene in cancer tissues samples were as follows: MAGE-A3, 70.8%; MAGE-A4, 46.9%; MAGE-C2, 61.1%; and NY-ESO-1, 15.0%. In all, Seventeen tissues did not express any of the CT antigens tested, 85.0% expressed at least one, 66.4% co-expressed two, 34.5% co-expressed three, 6.2% co-expressed four examined CT antigens. The percentage of samples co-expression HLA-A2 and CT genes were: MAGE-A3, 51.6%; MAGE-A4, 36.3%; MAGE-C2, 44.0%; and NY-ESO-1, 12.1%. MAGE-A3 was associated with male, smoking history, tumor stage, tumor differentiation and lymph node metastasis (P<0.05); MAGE-C2 was associated with tumor stage (P<0.05). There was no correlation MAGE-A4 or NY-ESO-1 expression with clinical characteristics such as gender, age, HLA-A2 positive, clinical stage, grade of differentiation and lymph node metastasis (P>0.05).

Conclusion

CT antigens might be prognostic markers and factors related to the progress of NSCLC, and also be served as the immunotherapeutic targets of NSCLC, especially in multi-antigen vaccine preparations and tumor antigen specific lymphocytes infusion.

Author information

Authors and Affiliations

  1. Biotherapy Center, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China

    Xin-Feng Chen, Meng Wang, Dong-Li Yue, Jin-Yan Liu, Lan Huang, Feng Li & Yi Zhang

  2. Department of Oncology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China

    Xin-Feng Chen, Dong-Li Yue & Yi Zhang

  3. Department of Thoracic Surgery, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China

    Song Zhao, Yu Qi, Wei Hu & Xiang-Nan Li

  4. Department of Biological Engineering, Zhengzhou University, Zhengzhou, China

    Yi Zhang

Authors
  1. Xin-Feng Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Meng Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dong-Li Yue
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jin-Yan Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Lan Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Feng Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Song Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Yu Qi
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Wei Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Xiang-Nan Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Yi Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Reprints and Permissions

About this article

Cite this article

Chen, XF., Wang, M., Yue, DL. et al. Expression of cancer-testis antigen in patients with non-small cell lung cancer and its clinical relevance. j. immunotherapy cancer 1 (Suppl 1), P246 (2013). https://doi.org/10.1186/2051-1426-1-S1-P246

Download citation

  • Published:

  • DOI: https://doi.org/10.1186/2051-1426-1-S1-P246

Keywords